본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Antibody System

[Antibodysystem] Losatuxizumab ELISA Kit

Cat-No. KDB86902



AntibodySystem는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다. 





제품 설명 

 

Losatuxizumab ELISA Kit

 



제품 번호


KDB86902




제품 특징

Catalog No.

KDB86902

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision


CV<20%


Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Losatuxizumab

Alternative Names

ABT-806, PR-1316749, CAS: 1801544-27-3

Background

Losatuxizumab is a biosimilar that targets EGFR. EGFR (Epidermal growth factor receptor, HER1, ErbB1) is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Phosphorylation of EGFR at certain residues is also mediated by Src-non-receptor kinase. EGFR activation signals multiple downstream signaling cascades such as the Ras - ERK, pi3-K - Akt, Jak - STAT and PKC pathways that help in growth and proliferation of cells. Phosphorylation of EGFR at Y1086 specifically allows binding of the adaptor protein GRB2, leading to activation of the MAPK pathway. Upon receptor activation and signaling, EGFR is endocytosed and targeted for degradation or recycling. Mutations in the EGFR gene are associated with lung cancer and multiple alternatively spliced transcript variants encode different protein isoforms of EGFR have been found. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. Moreover, EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Shipping

2-8 ℃

Note

For Research Use Only.




AntibodySystem의 모든 제품들을 만나 보세요!  


Products

Recombinant Protein

Antibody

Assay Kit

Research Biosimilar

Enzyme

Trending Product

Super-Affinity Antibody

Cell Lysates



Antibodysystem - Official Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"